Drug Trial Radar · NCT06430385
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intrathecally-Administered ION440 in Participants With Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome (MDS)
Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Oct 21, 2024
Primary completion
Sep 2027
Study completion Apr 2030
Sponsor
- Lead sponsor
- Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals (IONS)
- Sponsor type
- Industry
- First posted
- May 28, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 2 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the safety and tolerability of ION440.
Conditions
- Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Interventions
ION440Drug
ION440 will be administered by intrathecal bolus (ITB) injection.
Sham procedureProcedure
An LP will be performed with CSF collection but will not be followed by the administration of study treatment by ITB injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to approximately 36 weeks
- Part 1: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to approximately 36 weeks
- Part 1: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Baseline up to approximately 36 weeks
- Part 1: Number of Participants With Clinically Significant Change from Baseline in Laboratory AssessmentsTime frame: Baseline up to approximately 36 weeks
- Part 1: Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG)Time frame: Baseline up to approximately 36 weeks
- Part 2: Number of Participants With TEAEsTime frame: Up to approximately 192 weeks
- Part 2: Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Baseline up to approximately 192 weeks
- Part 2: Number of Participants With Clinically Significant Change From Baseline in Physical and Neurological Examination FindingsTime frame: Baseline up to approximately 192 weeks
- Part 2: Number of Participants With Clinically Significant Change from Baseline in Laboratory AssessmentsTime frame: Baseline up to approximately 192 weeks
- Part 2: Number of Participants With Clinically Significant Change From Baseline in ECGTime frame: Baseline up to approximately 192 weeks
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Rady Children's Hospital
San Diego, California · Recruiting
University of Colorado Hopsital - Anschutz Medical Campus
Aurora, Colorado · Recruiting
Kennedy Krieger
Baltimore, Maryland · Recruiting
Boston Children's Hospital
Boston, Massachusetts · Recruiting
Gillette Children's Specialty Healthcare
Saint Paul, Minnesota · Recruiting
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Baylor College of Medicine
Houston, Texas · Recruiting
Kepler University Hospital
Linz, Austria · Recruiting
British Columbia Children's Hospital
Vancouver, Canada · Recruiting
CHU Dijon Bourgogne
Dijon, France · Recruiting
Hospital Saint Joan de Deu
Barcelona, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.